

Georg Casari, cofounder, former senior vice president, and head of life science research of LION Bioscience has been appointed vice president, informatics at Cellzome (Heidelberg, Germany).

Genitope (Redwood City, CA) has announced the appointments of **Bonnie Charpentier** as vice president of regulatory affairs and **Tom DeZao** as vice president of strategic marketing and sales. Dr. Charpentier was previously vice president and regulatory site head of Roche Global Development, and Mr. DeZao was vice president of marketing at Corixa.



Robert M. Cook-Deegan has been selected director of the Center for Genome Ethics, Law and Policy at Duke University (Durham, NC). The author of *The Gene Wars: Science, Politics, and the*

Human Genome and other books, Dr. Cook-Deegan currently directs the Robert Wood Johnson Foundation Health Policy Fellowship program at the Institute of Medicine of the National Academy of Sciences. He is also a Robert Wood Johnson Health Policy Investigator at the Kennedy Institute of Ethics of Georgetown University.

Edward M. Fitzgerald has been appointed Ariad Pharmaceuticals' (Cambridge, MA) chief financial officer, senior vice president, and treasurer. He joins the company after four years as CFO and senior vice president of AltaRex.

Lothar Germeroth has been named chief executive officer of IBA GmbH (Göttingen, Germany). He joins the company from Cytos Biotechnology, where he served as chief business officer and CEO of Cytos Proteome Therapeutics. He was also previously CEO at Jerini AG.

William K. Heiden has been named president and chief operating officer at Praecis Pharmaceuticals (Waltham, MA). He joins the company from Schering-Plough, where he was most recently vice president of Schering's oncology/biotech business unit.

DeveloGen (Göttingen, Germany) has announced the appointment of **Günther Karmann** as chief executive officer, replacing cofounder **Herbert Stadler**, who will join the supervisory board. Dr. Karmann was head of the life sciences department at Bayer until March 2002. In addition, DeveloGen appointed **Thomas Metz** vice president, lead discovery and named **Helmut Schühlsler** to its board of

directors. Dr. Metz joins the company from Boehringer Ingelheim in Austria, and Dr. Schühlsler is managing partner at Techno Venture Management.

Trigen (London) has announced the appointments of **Tony Kennedy** as vice president, development and **Oliver Boucher** as vice president, commercial development. Dr. Kennedy was formerly global head of project management at Roche Pharma, and Mr. Boucher was formerly a director of business development at GlaxoSmithKline Biologicals.

Michael D. Kowolenko has been appointed vice president, global quality for Biogen (Cambridge, MA). Dr. Kowolenko joins the company from Bayer, where he was most recently vice president of quality assurance for the biological products business unit.

Bea Langton-Webster has been appointed vice president, drug development at Inologic (Seattle, WA). Prior to joining Inologic, she served as vice president, research and pre-clinical development at Cytran.

Genome Therapeutics (Waltham, MA) has announced the addition of **Timothy S. Leach** to the company's clinical development team as vice president of clinical and medical affairs. Dr. Leach served most recently as medical director at Cubist Pharmaceuticals.

Arradial (Bedford, MA) has named **Mark A. Tepper** president, CEO, and a member of its board of directors. Prior to joining the company, Dr. Tepper served as vice president, research and operations at the Serono Pharmaceutical Research Institute. In addition, **John R. Havens** has been named senior vice president, technology at Arradial. Dr. Havens was most recently senior director, chemistry and high-throughput screening at Nanogen.

Serono (Geneva) has appointed **Jacques Theurillat** as deputy CEO in addition to his responsibilities as chief financial officer. Mr. Theurillat joined Serono in 1987 as a corporate tax lawyer, and has served as CFO since 1996.

Genta (Berkeley Heights, NJ) has announced the appointment of **Douglas G. Watson** to the company's board of directors. Mr. Watson is the past president and CEO of Novartis' US subsidiary, and currently serves as a director on the boards of Dendreon and Engelhard Corp.

Raven Biotechnologies (S. San Francisco, CA) has named **John B. Whelan** as chief operating officer and chief financial officer. Mr. Whelan most recently served as vice president and CFO at Eos Biotechnology.